Review
C-kit as a target in the treatment of acute myelogenous leukemia
Affiliations
- PMID: 15610660
Item in Clipboard
Review
C-kit as a target in the treatment of acute myelogenous leukemia
Curr Hematol Rep.
2005 Jan.
Abstract
Acute myelogenous leukemia (AML) is a difficult disease to treat. Novel treatment strategies, including molecular targeted therapy, are currently being explored. The c-kit receptor represents a potential therapeutic target for AML. The receptor is expressed on more than 10% of blasts in 64% of de novo AMLs and 95% of relapsed AMLs. C-kit mediates proliferation and anti-apoptotic effects in AML. This review will discuss the biology of c-kit in normal and malignant hematopoiesis, and the recent clinical trials targeting c-kit in AML.
Similar articles
-
Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.Curr Hematol Malig Rep. 2006 Jun;1(2):101-7. doi: 10.1007/s11899-006-0020-9. Curr Hematol Malig Rep. 2006. PMID: 20425339 Review.
-
Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.Curr Hematol Rep. 2005 Jan;4(1):77-84. Curr Hematol Rep. 2005. PMID: 15610664 Review.
-
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.Cancer Res. 2006 Sep 1;66(17):8715-21. doi: 10.1158/0008-5472.CAN-05-4665. Cancer Res. 2006. PMID: 16951187
-
Current management of GIST.Clin Adv Hematol Oncol. 2004 May;2(5):280, 283. Clin Adv Hematol Oncol. 2004. PMID: 17682286 No abstract available.
-
Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.Eur J Pharmacol. 2006 Mar 8;533(1-3):327-40. doi: 10.1016/j.ejphar.2005.12.067. Epub 2006 Feb 17. Eur J Pharmacol. 2006. PMID: 16483568 Review.
Cited by
-
Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing.Exp Hematol Oncol. 2023 Mar 6;12(1):25. doi: 10.1186/s40164-023-00391-5. Exp Hematol Oncol. 2023. PMID: 36879313 Free PMC article.
-
Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia.Cell Oncol (Dordr). 2019 Apr;42(2):117-130. doi: 10.1007/s13402-018-0414-4. Epub 2018 Nov 16. Cell Oncol (Dordr). 2019. PMID: 30446944 Review.
-
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.Cancer Res. 2009 May 1;69(9):3910-7. doi: 10.1158/0008-5472.CAN-08-0034. Epub 2009 Apr 21. Cancer Res. 2009. PMID: 19383925 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources